There is an awful lot of future success priced into the shares already, and it would be unrealistic to expect anything other than a re-rating to the 45 - 50 cent range.
AVX has gotten way ahead of itself. The current sp reflects advanced Phase III trial progress, yet there are still many issues to overcome.
